Document:

<PAGE>
                                                                   Exhibit 10.61

                              CONSULTING AGREEMENT

            AGREEMENT, dated as of July 9, 2001, between Bio-Plexus, Inc (the
"Company"), and KST Consulting (the "Consultant").

                              W I T N E S S E T H:

            WHEREAS, the Company desires to engage the Consultant to provide
consulting services to the Company for the period provided herein upon the terms
and conditions set forth herein;

            WHEREAS, the Consultant is willing, and free, to provide the
consulting services to the Company as contemplated by this agreement;

            NOW, THEREFORE, in consideration of the foregoing and the mutual
covenants and agreements herein contained, and intending to be legally bound
hereby, the Company and the Consultant hereby agree as follows:

            1. CONSULTING PERIOD. The term of this Agreement shall commence upon
the Effective Date and shall continue for an initial period of two years, or
such other period as shall be mutually agreed between the parties (the
"Consulting Period") and for any period thereafter as may be agreed to by the
parties in writing unless sooner terminated as provided herein. The parties may
agree to extend this Agreement beyond the initial Consulting Period upon such
terms as shall be mutually agreed to in writing. "Effective Date" shall have the
meaning ascribed to such term in the Company's Plan of Reorganization dated as
of July 19, 2001.

            2. DUTIES. The Consultant agrees to provide advisory and consulting
services with respect to the business of the Company as may be from time to time
requested by the Company during the term of the Agreement. The services will
include, without limitations, sales and marketing assistance, strategic
planning, organizational structuring, strategies and financial planning. The
Consultant will not engage in other business activities, while a consultant to
the Company, which would conflict directly with the performance of its duties
under this Agreement, unless the Executive Officer has determined that no
significant conflict exists. In performing its duties for the Company, the
Consultant will report to the Chief Executive Officer or such other person as
may fill such position. The Consultant shall perform the consulting services at
such locations, as the parties shall agree to be appropriate. The Consultant
will devote, on average, a minimum of 25 hours per week in performance of the
above duties, and will maintain such records as requested by the Board to
document satisfaction of this requirement.

(a)   3. COMPENSATION/EXPENSES. As compensation for the consulting services to
      be rendered under this Agreement, the Company agrees to pay the Consultant
      $15,000 per month for the first 5 months and $12,000 per month thereafter
      payable in arrears on the 5th day of the month. The first Payment shall be
      made on or about August 5, 2001.
<PAGE>
(b)   The company shall grant the Consultant 100,000 options, 50,000 of which
      vest upon the first anniversary of this Agreement, and 50,000 which vest
      upon the second anniversary. Upon the occurrence of a Change of Control
      (to be defined in the Option Agreement), all options will vest
      immediately.

(c)   The Company agrees to reimburse the Consultant for approved travel
      expenses on the Company's business in accordance with the Company's travel
      expense policies as in effect from time to time upon presentation of
      proper documentation therefor; provided that the Chief Executive Officer
      has approved such travel expenses in advance.

            4. TERMINATION. The Consulting Period may be terminated upon written
consent of both parties. The Consultant may also be immediately terminated at
the option of the Company prior to the end of the initial or any renewal
Consulting Period, by notice to the Consultant, for Cause. Cause shall mean (i)
dishonesty, gross negligence or malfeasance by the Consultant in the performance
of its duties, (ii) acts which are injurious to the reputation, business or
goodwill of the Company or conduct which is scandalous, immoral or achieves
general notoriety in the community, (iii) the failure of the Consultant to
substantially perform its duties hereunder, or (iv) the breach by Consultant of
its obligations under this or any other agreement with the Company.

            5. INDEPENDENT CONTRACTOR. It is the express intention of the
parties that the Consultant render its services hereunder in the capacity of an
independent contractor and that the Company shall not have the right to direct,
control or supervise the Consultant in the performance of such services. In
keeping with this status, the Consultant shall be free to control its method of
work within the framework of its obligation to the Company. The Consultant shall
not be treated as an employee, officer or agent of the Company for any purpose,
and the Consultant shall not participate in or have any rights under any
employee benefit plans or other compensation arrangements maintained by the
Company for its employees. It is also understood that the Consultant shall not
have the power or authority to supervise, direct or manage any employee of the
Company, or to enter into contracts on behalf of the Company or to borrow or
incur debts or liabilities on behalf of the Company of any kind or nature
whatsoever. The Consultant shall be responsible for obtaining all necessary
licenses and permits for the conduct of Consultant's business and in all other
ways to fully comply with the requirements of applicable laws. Consultant shall
provide its own business cards indicating its trade name or, with the permission
of the Company, that it is on assignment to the Company.

            6. CONFIDENTIALITY. The Consultant agrees to abide by any
confidentiality agreement between the Company and any Prospect and to keep
secret and retain in the strictest confidence all confidential matters of the
Company, its clients, and any Prospect and not to disclose any such information
to anyone outside of the Company, except in the course of performing the
consulting services hereunder or as may be required by law. The Consultant also
agrees that all records, files and other memoranda made or kept by the
Consultant in connection with the consulting services rendered by the Consultant
under this Agreement shall be the exclusive property of the Company. The
Consultant agrees to return to the Company all records, documents, files and
other records relating to the business of the Company and its clients and all
copies thereof in whatever media.

            7. PROPERTY INFORMATION. In providing services to the Company under
this Agreement, Consultant agrees that it shall not use or disclose any
confidential or proprietary information or

                                       2
<PAGE>
            trade secrets belonging to any other persons, and shall not bring
            into the Company's premises any non-published document or any other
            property belonging to any such persons, unless consented to in
            writing by such persons.

                  8. POWER TO ENTER INTO AGREEMENT. The Consultant represents
            and warrants that it is free to enter into this Agreement and that
            its performance of services under this Agreement will not result in
            a breach of, or constitute a default under, any agreement or
            understanding to which the Consultant is a party or by which it may
            be bound.

                  9. NO ASSIGNMENT OR WAIVER. Neither party may assign any of
            its rights or delegate any of its duties under this Agreement. Any
            attempted assignment in violation of this provision shall be void.
            The failure of a party to insist upon strict adherence to any term
            of this Agreement on any occasion shall not be considered a waiver
            or deprive that party of the right hereafter to insist upon strict
            adherence to that term or any other term of this Agreement. Any
            waiver must be in writing.

                  10. ENTIRE AGREEMENT. This Agreement contains the entire
            agreement between the Consultant and the Company with respect to the
            consulting services to be provided by the Consultant. It may not be
            changed orally but only by a written agreement signed by each of the
            parties.

                  11. ENFORCEABILITY AND APPLICABLE LAW. The invalidity or
            unenforceability of any provision of this Agreement, in any respect,
            shall not affect the validity or enforceability of such provision in
            any other respect or of any other provisions of this Agreement, all
            of which shall remain in full force and effect. This Agreement and
            all amendments hereof shall be governed by the laws of the State of
            Connecticut.

                  12. ADDITIONAL INDEMNIFICATION. The Company shall, to the full
            extent permitted by Section 145 of the General Corporation Law of
            the State of Delaware, as amended from time to time, indemnify
            Consultant. The indemnification and advancement of expenses provided
            by, or granted pursuant to, this Agreement shall not be deemed
            exclusive of any other rights to which Consultant may be entitled
            under the By-Laws or any agreement, action of shareholders or
            disinterested directors or otherwise, both as to action in
            Consultant's official capacity and as to action in another capacity
            while retained by the Company, and shall inure to the benefit of the
            heirs, executors, and administrators of such Consultant. The
            indemnification obligations of the Company to the Consultant shall
            specifically include coverage for claims relating to Consultant's
            actions on behalf of the Company prior to the Effective Date.

                                       3
<PAGE>
            IN WITNESS WHEREOF, the parties have executed this Agreement as of
the date first above set forth.

                                    BIO-PLEXUS INC.

                                    By: __________________________________
                                           Name:
                                           Title:

                                    KST CONSULTING

                                    By: __________________________________
                                           Name: Scott Tepper
                                           Title:

                                       4<PAGE>
                                                                 EXHIBIT 10(p.1)

Note: Certain portions of this document have been marked "[c.i.]" to indicate
that confidential treatment has been requested for this confidential
information. The confidential portions have been omitted and filed separately
with the Securities and Exchange Commission.

                  AMENDMENT TO PURCHASE AND SUPPLY AGREEMENT

This Amendment to Purchase and Supply Agreement (the "Amendment"), effective as
of February 15, 2001, is made by and between DUSA Pharmaceuticals, Inc., a New
Jersey corporation, having offices at 25 Upton Drive, Wilmington, Massachusetts
01887 ("DUSA") and North Safety Products, Inc., a Delaware corporation and unit
of Norcross Safety Products L.L.C., having offices at 2000 Plainfield Pike,
Cranston, Rhode Island 02921 ("NSP").

Whereas, DUSA and NSP are parties to a Purchase and Supply Agreement effective
as of September 13, 1999 (the "Agreement");

Whereas, DUSA confirms that it will not order at least [c.i.] Kerastick(R) units
for delivery during the period from the first anniversary to the second
anniversary of this Agreement, and that as a result the parties intend to
negotiate a new agreement prior to the second anniversary of the Agreement,
i.e., September 13, 2001; and

Whereas, the parties wish to amend the Agreement upon the terms and conditions
set forth in this Amendment for good and valuable consideration which is hereby
acknowledged;

Now, Therefore, in consideration of the covenants, conditions, and undertakings
hereinafter set forth, the parties mutually agree as follows:

1.  The recitals above are incorporated into this Agreement.

2.  Amend Article II Supply by adding the following:

         2.4.3  Under-Utilization Fee.

                  (a) The parties recognize that orders for DUSA's Kerastick(R)
         have not been at unit levels as originally anticipated by the parties.
         DUSA agrees, therefore, to compensate NSP in the form of an
         under-utilization fee, for direct labor and overhead costs directly
         related to the manufacture of the Kerastick(R). The parties agree that
         NSP has substantiated such direct labor and overhead costs to DUSA's
         satisfaction supporting the [c.i.] maximum monthly charge described
         below. On a quarterly basis commencing September 30, 2001, NSP shall
         submit to DUSA documentation in the same form previously submitted
         demonstrating the then current direct labor costs related to
         manufacture of the Kerastick(R). Any changes in direct labor costs as
         compared to those utilized in calculation of the then applicable
         current maximum monthly under-utilization charge shall result in a
         change for the subsequent quarter to the then applicable maximum
         monthly charge, calculated utilizing the same methodology utilized in
         calculating the [c.i.] maximum charge. No further information shall be
         required and no changes shall be made with regard to overhead related
         to the manufacture of the Kerastick(R). For the period November 1, 2000
         to December 31, 2000, the parties have agreed and DUSA has paid an
         under-utilization fee of Eighty Five Thousand Fifty-Three Dollars
         ($85,053.00).

<PAGE>
Note: Certain portions of this document have been marked "[c.i.]" to indicate
that confidential treatment has been requested for this confidential
information. The confidential portions have been omitted and filed separately
with the Securities and Exchange Commission.

                  (b) If, based upon firm orders placed by DUSA under Section
         2.4.1 above, during the calendar year 2001, NSP manufactures less than
         [c.i.] units of Kerastick(R), or equivalent labor associated with DUSA
         activities performed by NSP (e.g., DUSA requested rework of units or
         clinical supplies) on a per month basis, (or [c.i.] units for the year)
         then DUSA shall pay to NSP an under-utilization fee up to [c.i.] per
         month (subject to change as specified in paragraph (a) above), payable
         on a monthly basis within thirty (30) days of the date of an invoice
         from NSP. Actual monthly under-utilization fees shall be calculated on
         a [c.i.] by comparing the number of units manufactured per month to
         [c.i.] to determine the percentage of utilization. The percentage of
         under-utilization shall equal [c.i.] minus the percentage of
         utilization. The percentage of under-utilization shall be multiplied by
         [c.i.] (as it may have been adjusted pursuant to paragraph (a) above)
         minus any equivalent activities costs to determine if any amount is due
         to NSP. For example, if [c.i.] units are manufactured, and billed
         equivalent labor charges for other activities are [c.i.] in a month,
         the under-utilization fee is [c.i.] (i.e., [c.i.] = [c.i.] utilization,
         or [c.i.] under-utilization; [c.i.] x [c.i.] = [c.i.] minus [c.i.] =
         [c.i.]. Monthly payments shall be reconciled on a quarterly basis as
         provided in subparagraph 2.4.3 (d) below.

                  (c) If the total number of units of Kerastick(R) manufactured
         by NSP during calendar year 2001 equals or exceeds [c.i.] (including
         any units rightfully rejected by DUSA), then all under-utilization fee
         payments made to NSP by DUSA under this Section 2.4.3 shall be paid to
         DUSA within fifteen (15) days of the purchase order from DUSA which
         causes manufacturing of units to equal or exceed [c.i.]; provided that
         if DUSA's orders during the 2001 exceed North's capacity for production
         of Kerastick units during a normal shift, then North shall be entitled
         to reduce any payment due to DUSA under this section by the amount of
         any applicable overtime labor costs incurred to North to meet DUSA's
         supply requirements.

                  (d) The parties shall reconcile the number of units
         manufactured and shall adjust the total of any monthly payments made
         under this Section 2.4.3, to reflect the total number of units ordered
         during each calendar quarter, or portion thereof, commencing with the
         quarter ended March 31, 2001, and continuing for the quarters ending
         June 30, September 30 and December 31, 2001, if the parties have not
         entered a new agreement as anticipated in Section 10.1 below). By way
         of example, if total units manufactured for a calendar quarter is
         [c.i.], then the under-utilization fee for the quarter shall be [c.i.],
         i.e., [c.i.] = [c.i.] utilization, so [c.i.] x 3 = [c.i.] x [c.i.]
         under-utilization and [c.i.] would be due to NSP for the quarter.
         Similarly, for the calendar year ending 2001, if total units
         manufactured is [c.i.] Kerastick(R), then the total amount due to NSP
         is [c.i.], i.e., [c.i.] = [c.i.] utilization, so [c.i.] x 12 = [c.i.] x
         [c.i.] under-utilization, or [c.i.] is due to NSP for the year,
         entitling DUSA to a payment of [c.i.] from the earlier quarter;
         provided that there is no reduction for overtime due to North under
         subsection (c) above.

                  (e) With any invoice from NSP for under-utilization fees, NSP
         shall provide a report that indicates the number of units manufactured
         and/or the equivalent activities referenced in subsection (b) above,
         during the month, together with the lot and/or batch

                                      -2-
<PAGE>
Note: Certain portions of this document have been marked "[c.i.]" to indicate
that confidential treatment has been requested for this confidential
information. The confidential portions have been omitted and filed separately
with the Securities and Exchange Commission.

         information. DUSA shall provide a report to NSP no later than thirty
         (30) days following the end of each calendar quarter (assuming that
         DUSA has received invoices from NSP) indicating the quarterly and/or
         annual reconciliation calculation. The parties shall make any
         adjustments due to either party based upon the reconciliation within
         fifteen (15) days of the date of the report.

                  (f) If DUSA orders [c.i.] Kerastick(R) or more in any
         particular quarter, NSP agrees to manufacture such amount under the
         delivery terms provided in the Agreement, regardless of whether a
         lesser amount was ordered or forecast by DUSA in the prior quarter,
         subject however, to the proviso that NSP's normal shift capacity is
         [c.i.] units per month and that overtime capacity is also limited.

                  (g) So long as DUSA pays the under-utilization fees according
         to the terms provided in this Section 2.4.3, DUSA shall be relieved of
         its obligations under Section 2.4.1 to order certain percentages of
         forecasted amounts and there shall be no breach of the Agreement for
         failure to do so.

3. Further Amend Article II by adding a new sentence to Section 2.3 (Price) to
         read as follows:

                  "North shall, in addition, be entitled to charge DUSA for any
         applicable overtime charges resulting from purchase orders in excess of
         North normal shift capacity."

4. Further Amend Article II by amending Sections 2.8 and 2.8.1 to read as
         follows:

                           Section 2.8 Invoicing; Payment. NSP shall submit an
          invoice to DUSA (and title shall pass to DUSA) upon completion of the
          manufacture of the Product including all quality control procedures
          and inspections by NSP to verify that the Products conform fully with
          the Specifications, but prior to completion of designated third party
          inspection, release and acceptance testing that DUSA has requested
          pursuant to Section 3.3 in order for DUSA to comply with its own
          commitments. All invoices shall be sent to 25 Upton Drive, Wilmington,
          Massachusetts 01887, and each such invoice shall state the aggregate
          and unit price for Products in a given completed manufacturing batch,
          [c.i.] to the purchase or shipment initially [c.i.] hereunder. All
          payments hereunder shall be made in U.S. Dollars, by direct bank
          transfer to an account designated in NSP's invoice. NSP may ship any
          invoiced Product for which DUSA has [c.i.] within [c.i.] after
          completion of manufacture. NSP may [c.i.] if any undisputed invoices
          at the time of the scheduled shipment are more than [c.i.] beyond the
          due date thereof. Risk of loss relating to Products shall be borne by
          NSP until [c.i.] of the Products to [c.i.].

                  2.8.1 Provisional Payment. The Provisional Price due to NSP
          under this Section 2.8 shall be due and payable within [c.i.] from the
          DUSA's receipt of an invoice. The Provisional Price shall be based on
          the forecasted quantities for a particular calendar year.

                                      -3-
<PAGE>
Note: Certain portions of this document have been marked "[c.i.]" to indicate
that confidential treatment has been requested for this confidential
information. The confidential portions have been omitted and filed separately
with the Securities and Exchange Commission.

5. Amend Article X Term and Termination by amending Section 10.1 and Section
   10.2.2 as follows:

         Section 10.1 Term. The term of this Agreement shall commence on the
Effective Date and continue in full force and effect until December 31, 2002,
unless terminated earlier upon written agreement of the parties (as a result of
negotiating a new agreement by September 13, 2001 or otherwise) or unless
extended by written agreement of the parties.

         Section 10.2.2  [intentionally deleted]

Except as specifically provided in this Amendment, all of the provisions of the
Agreement are and shall remain in full force and effect.

IN WITNESS WHEREOF, the parties have signed this Amendment to Purchase and
Supply Agreement effective as of the date stated above.

DUSA Pharmaceuticals, Inc.                          North Safety Products, Inc.

By: /s/ D. Geoffrey Shulman                         By: /s/ R. A. Peterson
    -----------------------                             ------------------------

Date:    5/25/01                                   Date:    5/24/01
      ---------------------                              ----------------------

                                      -4-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00035-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00035-of-00352.parquet"}]]